News of a vaccine sent the US financial markets soaring this week and there’s real hope that maybe we may have taken a giant step in dealing with the virus once and for all.

The company has seen its value grow by a whopping 431% since its Initial Public Offering. As a result, CureVac was able to get up to $231 million in initial funding, which is expected to go towards research and development.